Valamehr Bahram's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Mar 15, 2022
- Accession no.
- 0001209191-22-018820
- Filed
- Mar 15, 2022
- Trade date
- Mar 14, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $776.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valamehr BahramCIK 0001748177 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2022 | Common Stock | MOption exerciseAcquired | +25,000 | $2.73 | +$68,250 | 204,834 | Direct | |
| Mar 14, 2022 | Common Stock | SSaleDisposed | −16,678 | $30.36F2 | −$506,344.08 | 188,156 | Direct | |
| Mar 14, 2022 | Common Stock | SSaleDisposed | −3,067 | $31.66F3 | −$97,101.22 | 185,089 | Direct | |
| Mar 14, 2022 | Common Stock | SSaleDisposed | −2,195 | $32.49F4 | −$71,315.55 | 182,894 | Direct | |
| Mar 14, 2022 | Common Stock | SSaleDisposed | −2,960 | $33.30F5 | −$98,568 | 179,934 | Direct | |
| Mar 14, 2022 | Common Stock | SSaleDisposed | −100 | $34.04 | −$3,404 | 179,834 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2022 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 36,156 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $30.00 to $30.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $31.00 to $31.99 per share.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold from $32.00 to $32.99 per share.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price of the shares sold from $33.00 to $33.91 per share.
Referenced by the price of 1 transaction in Table I.